Rôle de la pharmacogénétique dans le métabolisme et le transport des antirétroviraux

Translated title of the contribution: Role of pharmacogenetics in the metabolism and transport of antiretroviral drugs

Véronique Michaud, Jacques Turgeon, David Flockhart, Mark A. Wainberg

Research output: Contribution to journalArticle

Abstract

Wide intra- and inter-subject variability in antiretroviral drug response is observed. Pharmacotherapy of HIV-infected patients is challenging considering the great numbers of co-morbidities increasing the risk of drug-drug interactions. Drug-metabolism enzymes and drug-transporters regulate drug access to the systemic circulation, target cells and sanctuary sites; these factors determine pharmacokinetics and could explain variability in efficacy and adverse drug reactions associated with antiretroviral drugs. Notions related to the major enzymes (CYP450s and UGTs) involved in antiretroviral metabolism and drug-transporters are reviewed with an attention paid on genetic polymorphisms. Genetic polymorphisms affecting the activity or the expression of membrane proteins in the transport of drugs would be highlighted with examples such as neurotoxicity with efavirenz, nephrotoxicity with tenofovir, hepatotoxicity with nevirapine and hyperlibirubinemia associated with indinavir and atazanavir. The objective is to provide a better understanding on mechanisms involved in drug-disposition of antiretroviral helping out health care providers in the management of pharmacotherapy of HIV-infected patients.

Original languageFrench
Pages (from-to)157-174
Number of pages18
JournalVirologie
Volume15
Issue number3
DOIs
StatePublished - May 2011

Fingerprint

Pharmacogenetics
Pharmaceutical Preparations
Tenofovir
efavirenz
Genetic Polymorphisms
HIV
Indinavir
Nevirapine
Drug Therapy
Membrane Transport Proteins
Enzymes
Drug-Related Side Effects and Adverse Reactions
Drug Interactions
Health Personnel
Pharmacokinetics
Morbidity

Keywords

  • Antiretroviral drugs
  • Cytochromes p450
  • Drug-transporters
  • HIV
  • Pharmacogenetics
  • Pharmacokinetics

ASJC Scopus subject areas

  • Virology
  • Infectious Diseases

Cite this

Rôle de la pharmacogénétique dans le métabolisme et le transport des antirétroviraux. / Michaud, Véronique; Turgeon, Jacques; Flockhart, David; Wainberg, Mark A.

In: Virologie, Vol. 15, No. 3, 05.2011, p. 157-174.

Research output: Contribution to journalArticle

Michaud, V, Turgeon, J, Flockhart, D & Wainberg, MA 2011, 'Rôle de la pharmacogénétique dans le métabolisme et le transport des antirétroviraux', Virologie, vol. 15, no. 3, pp. 157-174. https://doi.org/10.1684/vir.2011.0405
Michaud, Véronique ; Turgeon, Jacques ; Flockhart, David ; Wainberg, Mark A. / Rôle de la pharmacogénétique dans le métabolisme et le transport des antirétroviraux. In: Virologie. 2011 ; Vol. 15, No. 3. pp. 157-174.
@article{9172caf7a68f4b7ca83d85c22a63038d,
title = "R{\^o}le de la pharmacog{\'e}n{\'e}tique dans le m{\'e}tabolisme et le transport des antir{\'e}troviraux",
abstract = "Wide intra- and inter-subject variability in antiretroviral drug response is observed. Pharmacotherapy of HIV-infected patients is challenging considering the great numbers of co-morbidities increasing the risk of drug-drug interactions. Drug-metabolism enzymes and drug-transporters regulate drug access to the systemic circulation, target cells and sanctuary sites; these factors determine pharmacokinetics and could explain variability in efficacy and adverse drug reactions associated with antiretroviral drugs. Notions related to the major enzymes (CYP450s and UGTs) involved in antiretroviral metabolism and drug-transporters are reviewed with an attention paid on genetic polymorphisms. Genetic polymorphisms affecting the activity or the expression of membrane proteins in the transport of drugs would be highlighted with examples such as neurotoxicity with efavirenz, nephrotoxicity with tenofovir, hepatotoxicity with nevirapine and hyperlibirubinemia associated with indinavir and atazanavir. The objective is to provide a better understanding on mechanisms involved in drug-disposition of antiretroviral helping out health care providers in the management of pharmacotherapy of HIV-infected patients.",
keywords = "Antiretroviral drugs, Cytochromes p450, Drug-transporters, HIV, Pharmacogenetics, Pharmacokinetics",
author = "V{\'e}ronique Michaud and Jacques Turgeon and David Flockhart and Wainberg, {Mark A.}",
year = "2011",
month = "5",
doi = "10.1684/vir.2011.0405",
language = "French",
volume = "15",
pages = "157--174",
journal = "Virologie",
issn = "1267-8694",
publisher = "John Libbey Eurotext",
number = "3",

}

TY - JOUR

T1 - Rôle de la pharmacogénétique dans le métabolisme et le transport des antirétroviraux

AU - Michaud, Véronique

AU - Turgeon, Jacques

AU - Flockhart, David

AU - Wainberg, Mark A.

PY - 2011/5

Y1 - 2011/5

N2 - Wide intra- and inter-subject variability in antiretroviral drug response is observed. Pharmacotherapy of HIV-infected patients is challenging considering the great numbers of co-morbidities increasing the risk of drug-drug interactions. Drug-metabolism enzymes and drug-transporters regulate drug access to the systemic circulation, target cells and sanctuary sites; these factors determine pharmacokinetics and could explain variability in efficacy and adverse drug reactions associated with antiretroviral drugs. Notions related to the major enzymes (CYP450s and UGTs) involved in antiretroviral metabolism and drug-transporters are reviewed with an attention paid on genetic polymorphisms. Genetic polymorphisms affecting the activity or the expression of membrane proteins in the transport of drugs would be highlighted with examples such as neurotoxicity with efavirenz, nephrotoxicity with tenofovir, hepatotoxicity with nevirapine and hyperlibirubinemia associated with indinavir and atazanavir. The objective is to provide a better understanding on mechanisms involved in drug-disposition of antiretroviral helping out health care providers in the management of pharmacotherapy of HIV-infected patients.

AB - Wide intra- and inter-subject variability in antiretroviral drug response is observed. Pharmacotherapy of HIV-infected patients is challenging considering the great numbers of co-morbidities increasing the risk of drug-drug interactions. Drug-metabolism enzymes and drug-transporters regulate drug access to the systemic circulation, target cells and sanctuary sites; these factors determine pharmacokinetics and could explain variability in efficacy and adverse drug reactions associated with antiretroviral drugs. Notions related to the major enzymes (CYP450s and UGTs) involved in antiretroviral metabolism and drug-transporters are reviewed with an attention paid on genetic polymorphisms. Genetic polymorphisms affecting the activity or the expression of membrane proteins in the transport of drugs would be highlighted with examples such as neurotoxicity with efavirenz, nephrotoxicity with tenofovir, hepatotoxicity with nevirapine and hyperlibirubinemia associated with indinavir and atazanavir. The objective is to provide a better understanding on mechanisms involved in drug-disposition of antiretroviral helping out health care providers in the management of pharmacotherapy of HIV-infected patients.

KW - Antiretroviral drugs

KW - Cytochromes p450

KW - Drug-transporters

KW - HIV

KW - Pharmacogenetics

KW - Pharmacokinetics

UR - http://www.scopus.com/inward/record.url?scp=79960383949&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960383949&partnerID=8YFLogxK

U2 - 10.1684/vir.2011.0405

DO - 10.1684/vir.2011.0405

M3 - Article

VL - 15

SP - 157

EP - 174

JO - Virologie

JF - Virologie

SN - 1267-8694

IS - 3

ER -